Correlation of Relapse-Free Survival With Neoadjuvant Treatment in Patients With Stage Iiia Non-Small Cell Lung Cancer

Maliarchuk, Kateryna A.; Ganul, Andrey V; Borisyuk, Bogdan O; Bororov, Leonid B.; Shevchenko, Anatoly; Sovenko, V.

doi:10.36740/wlek20220420105

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Лікування недрібноклітинного раку легені III стадії а (НМРЛ) незважаючи на комбіноване і комплексне лікування не дозволяє забезпечити високу виживаність -за даними Українського канцер-реєстру 58% пацієнтів живуть не більше року після постановки діагнозу [1]. У попередніх дослідженнях ми провели порівняльний аналіз виживання пацієнтів після НХТ, НХЛТ і НХТ + ад'ювантна ЛТ і встановили, що НХЛТ дає переваги щодо тривалості життя пацієнтів [2][3][4]. Встановлено, що найважливішим аспектом лікуваль-ної стратегії є токсичність лікування та ризики, які воно створює для пацієнтів.…”

Section: вступunclassified

Comparison of Early Treatment- Emergent Complications of Stage Iii a Non-Small Cell Carcinoma (Nsclc Stage Iii A) in Patients Treated With Neoadjuvant Chemoradiotherapy (Nhlt), (Ncht), and Neoadjuvant Chemotherapy and Adjuvant Radiation Therapy

Malyarchuk,

Ganul,

Borysyuk

et al. 2023

Clin. and prev. med.

View full text Add to dashboard Cite

Treatment of STAGE III A NSCLC is an extremely difficult problem for modern oncology, since the one-year survival rate from the moment of diagnosis according to the National Cancer Registry is up to 58%. At the same time, there is a situation of uncertainty in the clinical approach to the treatment of this pathology – neither NCCN nor other world scientific literature sources contain information regarding a specific treatment method. The advantage of none of the possible methods of treatment of stage III NSCLC (HCT, NHLT, HCT + adjuvant PT) is not proven in relation to others. The conducted study is devoted to comparing these methods in relation to each other and overall and relapse-free survival. According to the results of previous studies, the highest results of both general and relapse-free survival were shown by patients from the NHLT group. But an important aspect of treatment is the ratio of benefit and risk, that is, the number and severity of complications. The study and analysis of complications of treatment with the methods of NXT, NHLT and NXT + adjuvant PT was the task of the work. Goal. To investigate and determine the number of complications in groups with NCRT, NCT and NCT + adjuvant LT. Materials and methods. The study included 3 groups of patients – patients who received NHLT, NHT and NHT + adjuvant PT, a total of 304 people. All patients had the same chemotherapy regimen- Cisplatin / Docetaxel or Carboplatin / Paclitaxel, patients receiving radiation therapy received it in a total dosage of 30 Gy in both neoadjuvant and adjuvant regimens. The irradiation was carried out on the chest and mediastinum area. Patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy. In early works on this topic, an analysis of survival on the Kaplan and Mayer scale was carried out. The article describes the conduct and study of treatment complications that were recorded during the stay of patients in the hospital both during chemotherapy, radiation therapy and in the postoperative period.

show abstract

Section: вступunclassified

Comparison of Early Treatment- Emergent Complications of Stage Iii a Non-Small Cell Carcinoma (Nsclc Stage Iii A) in Patients Treated With Neoadjuvant Chemoradiotherapy (Nhlt), (Ncht), and Neoadjuvant Chemotherapy and Adjuvant Radiation Therapy

Malyarchuk,

Ganul,

Borysyuk

et al. 2023

Clin. and prev. med.

View full text Add to dashboard Cite

show abstract

Prospects of Neoadjuvant Chemoradiotherapy in Patients With Stage Iii a Non-Small Cell Lung Cancer as a Method of Improving Survival

Maliarchuk¹,

Ganul²,

Borisyuk³

et al. 2022

Wiad Lek

View full text Add to dashboard Cite

The aim: To study the survival rate and count the number of complications in groups with NCRT, NCT and NCT + adjuvant radiotherapy. Materials and methods: The studied patients were divided into three groups with a total number of 304 people, Patients who received neoadjuvant chemotherapy-149 people, who received neoadjuvant chemotherapy and adjuvant radiation therapy-90 people. Neoadjuvant chemoradiotherapy was performed in accordance with Cisplatin/Docetaxel or Carboplatin/Paclitaxel 4 Mg and simultaneous radiation therapy with a total radiation dose 30 gray with a single dose of 2 Mg. After neoadjuvant treatment, patients of all groups underwent radical surgery. It consisted of lobectomy, bilobectomy and pneumonectomy. Postoperative complications and the duration of stay in the clinic after surgery were studied. Survival was assessed on the Kaplan and Mayer scale. Results: The study analyzed the main results of treatment, which showed that the 5 years survival in the main group was 28.1±5.9 %, in the control groups-the first control group (neoadjuvant chemotherapy) - 10.4±3.8 % and the second control group (neoadjuvant chemotherapy and adjuvant radiation therapy) - 5.8±2.0 %, respectively. Conclusions: 1. The overall survival rate of patients receiving NCT compared to patients receiving neoadjuvant chemotherapy is higher than in the neoadjuvant chemotherapy group and 13 months higher than in the adjuvant radiation therapy group. 2. Patients who had the phenomenon of a complete morphological response have a significantly higher survival rate (45 and 39 months, respectively).

show abstract

Correlation of Relapse-Free Survival With Neoadjuvant Treatment in Patients With Stage Iiia Non-Small Cell Lung Cancer

Cited by 2 publications

References 14 publications

Comparison of Early Treatment- Emergent Complications of Stage Iii a Non-Small Cell Carcinoma (Nsclc Stage Iii A) in Patients Treated With Neoadjuvant Chemoradiotherapy (Nhlt), (Ncht), and Neoadjuvant Chemotherapy and Adjuvant Radiation Therapy

Comparison of Early Treatment- Emergent Complications of Stage Iii a Non-Small Cell Carcinoma (Nsclc Stage Iii A) in Patients Treated With Neoadjuvant Chemoradiotherapy (Nhlt), (Ncht), and Neoadjuvant Chemotherapy and Adjuvant Radiation Therapy

Prospects of Neoadjuvant Chemoradiotherapy in Patients With Stage Iii a Non-Small Cell Lung Cancer as a Method of Improving Survival

Contact Info

Product

Resources

About